Log in
Enquire now
‌

US Patent 10172922 Rapid-acting insulin compositions

Patent 10172922 was granted and assigned to Eli Lilly and Company on January, 2019 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent
0

Patent attributes

Patent Applicant
Eli Lilly
Eli Lilly
0
Current Assignee
Eli Lilly
Eli Lilly
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
101729220
Patent Inventor Names
Thomas Andrew Hardy0
Michael Edward Christe0
Date of Patent
January 8, 2019
0
Patent Application Number
152591010
Date Filed
September 8, 2016
0
Patent Citations Received
‌
US Patent 10646551 Rapid-acting insulin formulation comprising a substituted anionic compound
‌
US Patent 11324808 Rapid-acting insulin formulation comprising a substituted anionic compound
0
‌
US Patent 10925931 Rapid-acting insulin compositions
‌
US Patent 10881716 Rapid-acting insulin formulation comprising a substituted anionic compound
Patent Primary Examiner
‌
Amber D Steele
0
Patent abstract

The invention is a composition of human insulin or insulin analog that includes treprostinil and that has faster pharmacokinetic action than commercial formulations of existing insulin analog products.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 10172922 Rapid-acting insulin compositions

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.